Quest Diagnostics (DGX) Misses Q4 EPS by 3c, Revenues; Offers FY19 EPS/Revenue Guidance Below Consensus

Quest Diagnostics (NYSE: DGX) reported Q4 EPS of $1.36, $0.03 worse than the analyst estimate of $1.39. Revenue for the quarter came in at $1.84 billion versus the consensus estimate of $1.88 billion.

"In 2018 we grew revenues, adjusted earnings and cash from operations despite some challenges in the marketplace. Quest is well positioned once again in 2019 to deliver on our commitment to grow revenues and earnings, as our in-network status now extends to approximately 90% of commercially insured lives in the U.S.," said Steve Rusckowski, Chairman, CEO and President. "Our guidance for 2019 reflects significant reimbursement pressure offset by strong volume growth and continued execution of our Invigorate program. I am pleased to report our volumes for the year are off to a good start."

GUIDANCE:

Quest Diagnostics sees Q1 2019 EPS of $6.40, versus the consensus of $6.56. Quest Diagnostics sees Q1 2019 revenue of $7.6-7.75 billion, versus the consensus of $7.76 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Stride Inc. (LRN) Tops Q3 EPS by 17c, provides guidance
• Visa (V) earnings and revenue exceed estimates in Q2, shares rise